

Medical Coverage Policy | Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions



EFFECTIVE DATE: 02|01|2023

POLICY LAST UPDATED: 10|04|2023

OVERVIEW

The use of blood-derived growth factors, including recombinant platelet-derived growth factors (PDGFs) and platelet-rich plasma (PRP), has been suggested as a treatment for wounds or other miscellaneous non-orthopedic conditions, including but not limited to, diabetic ulcers, pressure ulcers, venous stasis ulcers, and surgical and traumatic wounds

This policy is only applicable to autologous platelet-rich plasma (PRP)

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

Medicare Advantage Plans

Autologous platelet-rich plasma (PRP) for the treatment of chronic non-healing diabetic wounds is covered when filed with a covered diagnosis (See coding section). All other indications are not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products

Use of platelet-rich plasma (ie, autologous blood-derived preparations) is considered not medically necessary for the treatment of acute or chronic wounds, including surgical wounds and nonhealing ulcers as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE

Benefits may vary among groups. Please refer to the appropriate section of the Benefit Booklet, Evidence of Coverage or Subscriber Agreement for services not medically necessary.

BACKGROUND

A variety of growth factors have been found to play a role in wound healing, including platelet-derived growth factor (PDGF), epidermal growth factor, fibroblast growth factors, transforming growth factors, and insulin-like growth factors. Autologous platelets are a rich source of PDGF, transforming growth factors (that function as a mitogen for fibroblasts, smooth muscle cells, and osteoblasts), and vascular endothelial growth factors.

Autologous platelet concentrate suspended in plasma, also known as platelet-rich plasma (PRP), can be prepared from samples of centrifuged autologous blood. Exposure to a solution of thrombin and calcium chloride degranulates platelets, releasing various growth factors, and results in the polymerization of fibrin from fibrinogen, creating a platelet gel. The platelet gel can then be applied to wounds or may be used as an adjunct to surgery to promote hemostasis and accelerate healing. In the operating room setting, PRP has been investigated as an adjunct to a variety of periodontal, reconstructive, and orthopedic procedures. For example, bone morphogenetic proteins are a type of transforming growth factor, and thus PRP has been used

in conjunction with bone-replacement grafting (using either autologous grafts or bovine-derived xenograft) in periodontal and maxillofacial surgeries.

PRP is distinguished from fibrin glues or sealants, which have been used for many years as a surgical adjunct to promote local hemostasis at incision sites. Fibrin glue is created from platelet-poor plasma and consists primarily of fibrinogen. Commercial fibrin glues are created from pooled homologous human donors; Tisseel® (Baxter International) and Hemaseel® (Haemacure Corp.) are examples of commercially available fibrin sealants. Autologous fibrin sealants can also be created from platelet-poor plasma.

For individuals who have chronic wounds who receive platelet-rich plasma (PRP), the evidence includes meta-analyses of a number of small controlled trials. Relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. In meta-analyses of individuals with lower extremity diabetic ulcers, PRP demonstrated an improvement over the control groups in complete wound closure and healing time, but moderate to high risk of bias and imprecision preclude drawing conclusions on other important outcomes such as recurrence, infection, amputation, and quality of life. In individuals with venous ulcers, PRP did not demonstrate an improvement over the control groups in complete wound closure, recurrence, wound infection or quality of life, although imprecision likely precluded identifying differences on these outcomes. In individuals with pressure ulcers, although PRP reduced wound size, other important outcomes such as complete wound closure were not measured. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have acute surgical or traumatic wounds who receive PRP, the evidence includes a systematic review and a number of small controlled trials. Relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. Current results of trials using PRP are mixed and the studies are limited in both size and quality. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Medicare Advantage Plans

In April 2021, CMS published an updated decision memo following the fourth reconsideration of the national coverage analysis stating that CMS will "cover autologous platelet-rich plasma (PRP) for the treatment of chronic non-healing diabetic wounds under section 1862(a)(1)(A) of the Social Security Act (the Act) for a duration of 20 weeks, when prepared by devices whose FDA cleared indications include the management of exuding cutaneous wounds, such as diabetic ulcers. Coverage of autologous PRP for the treatment of chronic non-healing diabetic wounds beyond 20 weeks will be determined by local Medicare Administrative Contractors (MACs).

Coverage of autologous PRP for the treatment of all other chronic non-healing wounds will be determined by local Medicare Administrative Contractors (MACs) under section 1862(a)(1)(A) of the Act

CODING

Medicare Advantage Plans and Commercial Products

The following code is covered when filed with a covered diagnosis for Medicare Advantage Plans and not medically necessary for Commercial Products.

G0465 Autologous platelet rich plasma (PRP) for diabetic chronic wounds/ulcers, using an FDA-cleared device (includes administration, dressings, phlebotomy, centrifugation, and all other preparatory procedures, per treatment)

[ICD-10-CM Diagnosis List](#)

The following code is not covered for Medicare Advantage Plans and not medically necessary for Commercial Products as it is used for non-diabetic chronic wounds/ulcers

G0460 Autologous platelet rich plasma for non-diabetic chronic wounds/ulcers, including phlebotomy,

centrifugation, and all other preparatory procedures, administration and dressings, per treatment

RELATED POLICIES

No applicable

PUBLISHED

Provider Update, December 2023

Provider Update, December 2022

Provider Update, April 2021

Provider Update, May 2020

Provider Update, May 2019

REFERENCES:

1. Centers for Medicare & Medicaid Services. National Coverage Analysis (NCA) Tracking Sheet for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4). 2020; <https://www.cms.gov/medicare-coverage-database/details/nca-tracking-sheet.aspx?NCAId=300&NCDId=217&ncdver=5&IsPopup=y&bc=AAAAAAAAACAQA&>. Accessed December 10, 2022.
2. National coverage determination (NCD) for blood-derived products for chronic non-healing wounds (270.3). Centers for Medicare and Medicaid Services. Effective date of version March 13, 2021. <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=217&ncdver=5&NCAId=260&bc=ACAAAAAAQAAA&>. Accessed December 7, 2022.
3. Association for the Advancement of Wound Care (AAWC). International Consolidated Venous Ulcer Guideline (ICVUG). 2015; <https://aawconline.memberclicks.net/assets/appendix%20c%20guideline%20icvug-textformatrecommendations-final%20v42%20changessaved18aug17.pdf>. Accessed December 13, 2022.
4. National Institute for Health and Clinical Excellence (NICE). Diabetic foot problems: prevention and management [NG19]. 2019; <https://www.nice.org.uk/guidance/ng19/resources/diabetic-foot-problems-prevention-and-management-pdf-1837279828933>. Accessed December 13, 2022.
5. Centers for Medicare & Medicaid Services. Decision Memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R3). 2012; <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=260>. Accessed December 11, 2022.
6. Centers for Medicare & Medicaid Services (CMS). CMS Manual System: Pub 100-3 Medicare National Coverage Determinations (Transmittal 127). 2010 Oct; <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R127NCD.pdf>. Accessed December 13, 2022.
7. Centers for Medicare & Medicaid Services. Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds (CAG-00190R2). 2008; <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=208>. Accessed December 12, 2022.
8. Centers for Medicare & Medicaid Services. Proposed Decision Memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4). 2020; <https://www.cms.gov/medicare-coverage-database/details/nca-proposed-decision-memo.aspx?NCAId=300&NCDId=217&ncdver=5&IsPopup=y&bc=AAAAAAAAACAQA&>. Accessed December 8, 2022.
9. Centers for Medicare & Medicaid Services. National Coverage Analysis (NCA) for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4). 2021; <https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=300>. Accessed December 9, 2022.
10. U.S. Food and Drug Administration. Guidance for Industry: Chronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment. Rockville, MD: Food and Drug Administration; 2006 June.
11. U.S. Food and Drug Administration (FDA). Tissue and Tissue Products. 2016; <http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/>. Accessed December 13, 2022.

12. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Becaplermin for wound healing. TEC Assessments. 1999; Volume 14: Tab 5.
13. Crovetti G, Martinelli G, Issi M, et al. Platelet gel for healing cutaneous chronic wounds. *Transfus Apher Sci.* Apr 2004; 30(2): 145-51. PMID 15062754
14. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. *Plast Reconstr Surg.* Nov 2004; 114(6): 1502-8. PMID 15509939
15. Kevy SV, Jacobson MS. Comparison of methods for point of care preparation of autologous platelet gel. *J Extra Corpor Technol.* Mar 2004; 36(1): 28-35. PMID 15095838
16. Castillo TN, Pouliot MA, Kim HJ, et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. *Am J Sports Med.* Feb 2011; 39(2): 266-71. PMID 21051428
17. Mazzucco L, Balbo V, Cattana E, et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, Regen PRP-Kit, Plateltex and one manual procedure. *Vox Sang.* Aug 2009; 97(2): 110-8. PMID 19392780
18. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Growth factors for wound healing. TEC Evaluations. 1992; 7:352-377.
19. Zhao XH, Gu HF, Xu ZR, et al. Efficacy of topical recombinant human platelet-derived growth factor for treatment of diabetic lower-extremity ulcers: Systematic review and meta-analysis. *Metabolism.* Oct 2014; 63(10): 1304-13. PMID 25060693
20. Sridharan K, Sivaramakrishnan G. Growth factors for diabetic foot ulcers: mixed treatment comparison analysis of randomized clinical trials. *Br J Clin Pharmacol.* Mar 2018; 84(3): 434-444. PMID 29148070
21. Margolis DJ, Bartus C, Hoffstad O, et al. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. *Wound Repair Regen.* Nov-Dec 2005; 13(6): 531-6. PMID 16283867
22. Rees RS, Robson MC, Smiell JM, et al. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. *Wound Repair Regen.* May-Jun 1999; 7(3): 141-7. PMID 10417749
23. Senet P, Vicaut E, Beneton N, et al. Topical treatment of hypertensive leg ulcers with platelet-derived growth factor- BB: a randomized controlled trial. *Arch Dermatol.* Aug 2011; 147(8): 926-30. PMID 21482863
24. Freedman BM, Oplinger EH, Freedman IS. Topical becaplermin improves outcomes in work related fingertip injuries. *J Trauma.* Oct 2005; 59(4): 965-8. PMID 16374289
25. Martinez-Zapata MJ, Marti-Carvajal A, Sola I, et al. Efficacy and safety of the use of autologous plasma rich in platelets for tissue regeneration: a systematic review. *Transfusion.* Jan 2009; 49(1): 44-56. PMID 18954394
26. Martinez-Zapata MJ, Marti-Carvajal AJ, Sola I, et al. Autologous platelet-rich plasma for treating chronic wounds. *Cochrane Database Syst Rev.* May 25 2016; (5): CD006899. PMID 27223580
27. Martinez-Zapata MJ, Marti-Carvajal AJ, Sola I, et al. Autologous platelet-rich plasma for treating chronic wounds. *Cochrane Database Syst Rev.* Oct 17 2012; 10: CD006899. PMID 23076929
29. Carter MJ, Fyelling CP, Parnell LK. Use of platelet rich plasma gel on wound healing: a systematic review and meta- analysis. *Eplasty.* 2011; 11: e38. PMID 22028946
30. Picard F, Hersant B, Bosc R, et al. The growing evidence for the use of platelet-rich plasma on diabetic chronic wounds: A review and a proposal for a new standard care. *Wound Repair Regen.* Sep 2015; 23(5): 638-43. PMID 26019054
31. Del Pino-Sedeno T, Trujillo-Martin MM, Andia I, et al. Platelet-rich plasma for the treatment of diabetic foot ulcers: A meta-analysis. *Wound Repair Regen.* Mar 2019; 27(2): 170-182. PMID 30575212
32. Li Y, Gao Y, Gao Y, et al. Autologous platelet-rich gel treatment for diabetic chronic cutaneous ulcers: A meta-analysis of randomized controlled trials. *J Diabetes.* May 2019; 11(5): 359-369. PMID 30182534
33. Qu W, Wang Z, Hunt C, Morrow AS, Urtecho M, Amin M, Shah S, Hasan B, Abd-Rabu R, Ashmore Z, Kubrova E, Prokop LJ, Murad MH. Platelet-Rich Plasma for Wound Care in the Medicare Population. Technology Assessment Program Project ID 040-353-492. (Prepared by the Mayo Clinic Evidence-based

- Practice Center under Contract No. HHS290201500013L) Rockville, MD: Agency for Healthcare Research and Quality. <https://www.ahrq.gov/sites/default/files/wysiwyg/research/findings/ta/prp/prp-wound-care.pdf>. Accessed December 13, 2022.
34. Ahmed M, Reffat SA, Hassan A, et al. Platelet-Rich Plasma for the Treatment of Clean Diabetic Foot Ulcers. *Ann Vasc Surg.* Jan 2017; 38: 206-211. PMID 27522981
 35. Chen HY, Chen CX, Liang Y, Wang J. Efficacy of autologous platelet rich gel in the treatment of refractory diabetic foot. *Chin J New Clin Med.* 2008; 17:1-2.
 36. Driver VR, Hanft J, Fylling CP, et al. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. *Ostomy Wound Manage.* Jun 2006; 52(6): 68-70, 72, 74 passim. PMID 16799184
 37. Elsaid A, El-Said M, Emile S, et al. Randomized Controlled Trial on Autologous Platelet-Rich Plasma Versus Saline Dressing in Treatment of Non-healing Diabetic Foot Ulcers. *World J Surg.* Apr 2020; 44(4): 1294-1301. PMID 31811339
 38. Friese G, Herten M, Scherbaum WA. The use of autologous platelet concentrate activated by autologous thrombin (APC+) is effective and safe in the treatment of chronic diabetic foot ulcers-a randomized controlled trial. In: eds. *Proceedings of the Fifth International Symposium on the Diabetic Foot*, May September 12, 2007, Noordwijkerhout, The Netherlands. 2007.
 39. Game F, Jeffcoate W, Tarnow L, et al. LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. *Lancet Diabetes Endocrinol.* Nov 2018; 6(11): 870-878. PMID 30243803
 40. Gude W, Hagan D, Abood F, et al. Aurix Gel Is an Effective Intervention for Chronic Diabetic Foot Ulcers: A Pragmatic Randomized Controlled Trial. *Adv Skin Wound Care.* Sep 2019; 32(9): 416-426. PMID 31436621
 41. Kakagia DD, Kazakos KJ, Xarchas KC, et al. Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. *J Diabetes Complications.* Nov-Dec 2007; 21(6): 387-91. PMID 17967712
 42. Karimi R, Afshar M, Salimian M, et al. The effect of platelet rich plasma dressing on healing diabetic foot ulcers. *Nurs Midwifery Stud.* 2016;5(3):e30314.
 43. Li L, Chen D, Wang C, et al. Autologous platelet-rich gel for treatment of diabetic chronic refractory cutaneous ulcers: A prospective, randomized clinical trial. *Wound Repair Regen.* Jul-Aug 2015; 23(4): 495-505. PMID 25847503
 44. Liu GY, Deng XL, Sun Y, Wang MZ, Gao J, Gou J. Effect of autologous platelet-rich gel on the treatment of diabetic foot ulcers. *J Xi'an Jiaotong Univ (Med Sci).* 2016; 37:264-267.
 45. Ma L. Clinical efficacy of autologous platelet rich gel in the treatment of diabetic foot and diabetic chronic cutaneous ulcer. *Chin J Mod Drug Appl.* 2014; 8:86-88
 46. Milek T, Baranowski K, Zydlewski P, et al. Role of plasma growth factor in the healing of chronic ulcers of the lower legs and foot due to ischaemia in diabetic patients. *Postepy Dermatol Alergol.* Dec 2017; 34(6): 601-606. PMID 29422826
 47. Qi KQ, Chen TJ P, Shang XL. The application of autologous platelet-rich gel in the treatment of diabetic foot ulcers. *Chin J Diabetes.* 2014;22: 1102-1105.
 48. Saad Setta H, Elshahat A, Elsherbiny K, et al. Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: a comparative study. *Int Wound J.* Jun 2011; 8(3): 307-12. PMID 21470370
 49. Saldalamacchia G, Lapice E, Cuomo V, et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. *Nutr Metab Cardiovasc Dis.* Dec 2004; 14(6): 395-6. PMID 15853123
 50. Serra R, Grande R, Butrico L, et al. Skin grafting and topical application of platelet gel in the treatment of vascular lower extremity ulcers. *Acta Phlebologica.* 2014 01 Dec;15(3):129-36.
 51. Singh SP, Kumar V, Pandey A, et al. Role of platelet-rich plasma in healing diabetic foot ulcers: a prospective study. *J Wound Care.* Sep 02 2018; 27(9): 550-556. PMID 30204574

53. Steed DL, Goslen JB, Holloway GA, et al. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. *Diabetes Care*. Nov 1992; 15(11): 1598- 604. PMID 1468291
54. Steed DL, Edington HD, Webster MW. Recurrence rate of diabetic neurotrophic foot ulcers healed using topical application of growth factors released from platelets. *Wound Repair Regen*. Apr-Jun 1996; 4(2): 230-3. PMID 17177818
55. Xie J, Fang Y, Zhao Y, et al. Autologous Platelet-Rich Gel for the Treatment of Diabetic Sinus Tract Wounds: A Clinical Study. *J Surg Res*. Mar 2020; 247: 271-279. PMID 31706541
56. Yang L, Gao L, Lv Y, et al. Autologous platelet-rich gel for lower-extremity ischemic ulcers in patients with type 2 diabetes. *International Journal of Clinical and Experimental Medicine*. 2017 30 Sep;10(9):13796-801.
57. Zhang L, Qiang D, Sun YH. Clinical observation of autologous platelet rich gel in the treatment of diabetic foot ulcers. *Ningxia Med J*. 2016;38:809-811.
58. Zhou XP, Gong YX, Yang ZD, Wang W. Application value analysis of autologous platelet gel in refractory skin ulcer of diabetic patients. *World Lat Med Inform*. 2015; 15:19-20
59. Zhu SF, Liu H, Li L, Wang XF. Preliminary application of autologous platelet rich gel in diabetic neuropathic ulcers. *Med Innov China*. 2012; 9:18-19.
60. Qu W, Wang Z, Hunt C, et al. The Effectiveness and Safety of Platelet-Rich Plasma for Chronic Wounds: A Systematic Review and Meta-analysis. *Mayo Clin Proc*. Sep 2021; 96(9): 2407-2417. PMID 34226023
61. Oliveira BGRB, Carvalho MR, Ribeiro APL. Cost and effectiveness of Platelet Rich Plasma in the healing of varicose ulcer: Meta-analysis. *Rev Bras Enferm*. 2020; 73(4): e20180981. PMID 32609173
62. Saha S, Patra AC, Gowda SP, et al. Effectiveness and safety of autologous platelet-rich plasma therapy with total contact casting versus total contact casting alone in treatment of trophic ulcer in leprosy: An observer-blind, randomized controlled trial. *Indian J Dermatol Venereol Leprol*. May-Jun 2020; 86(3): 262-271. PMID 31997794
63. Gupta A, Channaveera C, Sethi S, et al. Efficacy of Intralesional Platelet-Rich Plasma in Diabetic Foot Ulcer. *J Am Podiatr Med Assoc*. May 01 2021; 111(3). PMID 33231614
64. Zhou SF, Estrera AL, Loubser P, et al. Autologous platelet-rich plasma reduces transfusions during ascending aortic arch repair: a prospective, randomized, controlled trial. *Ann Thorac Surg*. Apr 2015; 99(4): 1282-90. PMID 25661906
65. Serraino GF, Dominijanni A, Jiritano F, et al. Platelet-rich plasma inside the sternotomy wound reduces the incidence of sternal wound infections. *Int Wound J*. Jun 2015; 12(3): 260-4. PMID 23692143
66. El-Anwar MW, Nofal AA, Khalifa M, et al. Use of autologous platelet-rich plasma in complete cleft palate repair. *Laryngoscope*. Jul 2016; 126(7): 1524-8. PMID 27075516
67. Sidman JD, Lander TA, Finkelstein M. Platelet-rich plasma for pediatric tonsillectomy patients. *Laryngoscope*. Oct 2008; 118(10): 1765-7. PMID 18622315
68. Almdahl SM, Veel T, Halvorsen P, et al. Randomized prospective trial of saphenous vein harvest site infection after wound closure with and without topical application of autologous platelet-rich plasma. *Eur J Cardiothorac Surg*. Jan 2011; 39(1): 44-8. PMID 20634084
69. Alamdari DH, Asadi M, Rahim AN, et al. Efficacy and Safety of Pleurodesis Using Platelet-Rich Plasma and Fibrin Glue in Management of Postoperative Chylothorax After Esophagectomy. *World J Surg*. Apr 2018; 42(4): 1046- 1055. PMID 28986682
70. Mohamadi S, Norooznezhad AH, Mostafaei S, et al. A randomized controlled trial of effectiveness of platelet-rich plasma gel and regular dressing on wound healing time in pilonidal sinus surgery: Role of different affecting factors. *Biomed J*. Dec 2019; 42(6): 403-410. PMID 31948604
71. Slaninka I, Fibir A, Kaska M, et al. Use of autologous platelet-rich plasma in healing skin graft donor sites. *J Wound Care*. Jan 02 2020; 29(1): 36-41. PMID 31930949
72. Kazakos K, Lyras DN, Verettas D, et al. The use of autologous PRP gel as an aid in the management of acute trauma wounds. *Injury*. Aug 2009; 40(8): 801-5. PMID 18703188

74. Marck RE, Gardien KL, Stekelenburg CM, et al. The application of platelet-rich plasma in the treatment of deep dermal burns: A randomized, double-blind, intra-patient controlled study. *Wound Repair Regen.* Jul 2016; 24(4): 712-20. PMID 27169627
75. Yeung CY, Hsieh PS, Wei LG, et al. Efficacy of Lyophilised Platelet-Rich Plasma Powder on Healing Rate in Patients With Deep Second Degree Burn Injury: A Prospective Double-Blind Randomized Clinical Trial. *Ann Plast Surg.* Feb 2018; 80(2S Suppl 1): S66-S69. PMID 29369904
76. Huang H, Sun X, Zhao Y. Platelet-rich plasma for the treatment of burn wounds: A meta-analysis of randomized controlled trials. *Transfus Apher Sci.* Feb 2021; 60(1): 102964. PMID 33127309
77. Qaseem A, Humphrey LL, Forcica MA, et al. Treatment of pressure ulcers: a clinical practice guideline from the American College of Physicians. *Ann Intern Med.* Mar 03 2015; 162(5): 370-9. PMID 25732279
78. Association for the Advancement of Wound Care (AAWC). *Guideline of Pressure Ulcer Guidelines.* Malvern, PA: AAWC; 2010.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

